Preclinical Development of miR-10B Antagonist for the Treatment of Glioblastoma. Preclinical Development of miR-10B Antagonist for the Treatment of Glioblastoma Post navigation Previous: RGLS4326 Confers Efficacy and Modulate Aberrant Signaling and Metabolic Pathways in PKD Mouse ModelsNext: Discovery of Anti-miR-17 Oligonucleotide RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
